차입 증가 → 이자부담 → 수익성 악화
Critical부채가 +7.8% 늘며 이자보상배율이 54.6x에서 49.8x로 하락했다. ROE도 32.6%에서 30.2%로 낮아져 차입 부담이 수익성을 누르고 있다.
Evidence
부채 YoY +7.8%이자보상배율 54.6x→49.8xROE 32.6%→30.2%
CME Group Class A
CME-US · Nasdaq$267.79+0.21%
2026-07-31 closeCME Group Class A — pricey right now, or cheap? And what signals are flashing today?
Open the exact grade & valuation bands with Pro →Loading chart…
Close
1 guru reporting 13F holdings — George SorosAI Insight
Why these signals fired — only backtest-proven edge, told honestly
Strong-buy signal — the real recordrecord · not a prediction
Not this one stock, but every strong-buy pick we actually published (US market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)
Last 30 sessions
759 picks
Next-day win rate
58.8%
Avg next-day
+0.55%
vs market
+0.45%p
Beat the market on 57.6% of picks (each pick vs its own day’s market average).
Recent publish days (next-day win rate)
07-30 27.3%07-29 30.8%07-28 11.1%07-27 50%07-24 28.6%07-23 44.4%07-22 50%07-21 60%07-20 33.3%07-17 37.5%07-16 16.7%07-15 50%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.
Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.
Valuation Grades
Relative to 97 증권 peers · not investment advice
Valuation in its own history
PER 28.07 · PBR 3.74 — own history (2002-12~) percentiles 50/100 · 25/100
PER50/100
PBR25/100
Higher indicates lower valuation relative to its history (based on earnings and book yields).
Earnings percentiles can fluctuate for cyclical companies (including loss periods), so the book basis is shown alongside. Companies with large share buybacks can have structurally high PBR. Factual information, not investment advice.
Annual dividend
Split-adjusted annual DPS history and available grade axes
Paid 23 consecutive years · Raised 6 consecutive years · Yield 4.03% (based on 2025 payment of $10.80) · 3-year growth +14.2%
Per-share amount adjusted for splits and capital reductions · Factual information, not investment advice.
Financial safety
Reference indicatorAs of 2024Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' 0.78
Distress
Grey
Safe
- Altman Z''
- 0.78
- Beneish M-Score
- -2.45
- Sloan accrual
- -0.12%
No statistical flag
부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.
Factual information, not investment advice.
Why has this company moved this way?
Auditable observations with the original numeric evidence.
Factual information, not investment advice.
Earnings quality · Piotroski F-Score
4/9Moderate
Piotroski measures year-over-year financial improvement, not absolute quality.
Financial improvement score4/9
Profitability
- Positive ROAPass
- Positive OCFPass
- Improving ΔROAPass
- Accruals (OCF > net income)Pass
Leverage & liquidity
- Lower debtNot passed
- Higher current ratioNot passed
- No new sharesNot passed
Efficiency
- Higher gross marginNot passed
- Higher asset turnoverNot passed
Calculation note: F7(신주)은 equity/asset 유지로 근사
Already-stable companies may score lower when year-over-year improvement is limited.
Factual information, not investment advice.
Industry structure
USAs of 2026-08-03증권
This stock is in 증권: revenue rank 16 of 80, share 1.3%.
16 / 801.3%revenue share
Who dominates this industry?
- 1StoneX Group17.4%
- 2Goldman Sachs Group16.7%
- 3Morgan Stanley14.1%
- 4BROOKFIELD A (NYS)11.3%
- 5Charles Schwab3.4%
- 6CME Group Class A1.3%
Concentration
DistributedCR3 48.1%HHI and CR3 are separate industrial-organization facts; they are not the polarization verdict.
Polarization
Winner-take-all deepeningConsistentPolarization measures industry gaps and structure, not valuation, forecast, or investment advice.
Margin lens
- IQR%p
- 58.06
- Direction
- 확대
- Level
- 넓음
- Years
- 7
Value lens
- P90/P10
- 18
- Median P/B
- 3.72
- Level
- 넓음
- n
- 65
Survivorship note: 현재 산업 멤버십을 과거 연도에 소급 적용 — 과거 진입·퇴출 기업 미반영(복원 불가)
Factual information, not investment advice.
Risk sensitivity — adverse assumptions
Metric changes under stated assumptions; not a forecast or investment advice.
Base metrics
- Operating margin
- 78.5%
- Interest coverage
- 49.8x
- Return on equity (ROE)
- 13.3%
Operating margin −5pp
TolerableInterest coverageBase 49.8x adverse case 46.6x
Return on equity (ROE)Base 13.3% adverse case 27.7%
Revenue −15%
TolerableInterest coverageBase 49.8x adverse case 42.3x
Return on equity (ROE)Base 13.3% adverse case 25.1%
Interest rate +2pp
TolerableInterest coverageBase 49.8x adverse case 3.4x
Return on equity (ROE)Base 13.3% adverse case 21.3%
Interest coverage limit
Current margin 76.9ppInterest coverage limit at an operating margin of 1.6%
Interest expense coverage threshold
Financials at a glance
CME Group Class A's latest results and balance sheet. The bars track the last three periods.
Who held it · filings
Filed recordA historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.
US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.
Curated gurus reporting this holding
A curated subset of well-known investors — not the full institutional ownership.
- Soros Fund Management30,028주2026-03-31 · 증감 0주
Connections
AI-extracted related companies · for reference
Customers
Competitors
📦 ETFs holding this stock
by weight · top-10 constituents basisPassive money holding this stock ≈ $337M(lower bound — top-10 basis, not a forecast)
Factual holdings info from daily disclosures — not a recommendation.
Look up another stock →Recent filings
Filings for overseas stocks are on the way. For now we cover Korean stocks only.
Like these rules? Run them automatically.
Quantus turns rules like these into backtests and automated trading — same team, free to start.
Quantus Signal · live data · not investment advice · Privacy Policy